{"id":16238,"date":"2011-11-22T00:21:16","date_gmt":"2011-11-22T05:21:16","guid":{"rendered":"http:\/\/1boringoldman.com\/?p=16238"},"modified":"2011-11-22T03:15:19","modified_gmt":"2011-11-22T08:15:19","slug":"2006-2","status":"publish","type":"post","link":"https:\/\/1boringoldman.com\/index.php\/2011\/11\/22\/2006-2\/","title":{"rendered":"2006…"},"content":{"rendered":"\n

Those of you who have been at this a while must giggle at people like me who are new to the scene as we discover things that you’ve known for a long time. I’ve been at this for a while now. I know that because I start looking something up, and find a link to something I personally already wrote, but hadn’t connected my new line of investigation. That happened yesterday. I was looking at the things Martin Keller signed onto after Study 329 [which was brought into question as soon as it was published in 2001] and I ran into the article below [again]. Here’s how I reproduced the abstract back in October [the apogee…<\/font><\/a><\/strong><\/u>]:<\/p>\n\n\n
\n
\n
Impact of Publicity Concerning Pediatric Suicidality Data on Physician Practice Patterns in the United States<\/font><\/strong><\/u><\/a>
by Charles B. Nemeroff, Amir Kalali<\/font>, Martin B. Keller, Dennis S. Charney, Susan E. Lenderts, Elisa F. Cascade, Hugo Stephenson<\/font>, and Alan F. Schatzberg<\/sup>
Archives of General Psychiatry<\/font><\/strong>. 2007 64(4):466-472.<\/div>\n

<\/p>\n

…<\/font><\/strong>
Conclusions:<\/font><\/strong><\/u> The effect on antidepressant prescribing volume observed in our analysis of the Verispan data parallels earlier findings reported by Medco Health Solutions, Inc, and NDC Health that the FDA actions have had a significant effect on the prescribing of antidepressants to children and adolescents. Together, these findings underline the importance of presenting a fair balance within the media due to the significant reach of this channel among prescribing physicians.<\/sup><\/div>\n<\/blockquote>\n
I usually leave off the Author’s Financial Disclosures, but in this case, they seemed pertinent: <\/div>\n
\n
Dr Nemeroff<\/font><\/strong><\/u> has received grants from or performed research for the American Foundation for Suicide Prevention, AstraZeneca, Bristol-Myers Squibb, Forest Laboratories, Inc, Janssen Pharmaceutica, NARSAD: The Mental Health Research Association, the National Institute of Mental Health, Pfizer Pharmaceuticals, and Wyeth-Ayerst Laboratories; has been a consultant to Abbott Laboratories, Acadia Pharmaceuticals, Bristol-Myers Squibb, Corcept Therapeutics, Cypress Bioscience, Cyberonics, Eli Lilly and Co, Entrepreneur’s Fund, Forest Laboratories, Inc, GlaxoSmithKline, i3 DLN, Janssen Pharmaceutica, Lundbeck, Otsuka America Pharmaceutical, Inc, Pfizer Pharmaceuticals, Quintiles Transnational<\/font><\/strong>, UCB Pharma, and Wyeth-Ayerst Laboratories; has been on the speakers bureau for Abbott Laboratories, GlaxoSmithKline, Janssen Pharmaceutica, and Pfizer Pharmaceuticals; is a stockholder in Acadia Pharmaceuticals, Corcept Therapeutics, Cypress Bioscience, and NovaDel Pharma Inc; is on the board of directors of the American Foundation for Suicide Prevention, the American Psychiatric Institute for Research and Education, the George West Mental Health Foundation, NovaDel Pharma Inc, and the National Foundation for Mental Health; holds patents on a method and devices for transdermal delivery of lithium [US 6,375,990 B1] and on a method to estimate serotonin and norepinephrine transporter occupancy after drug treatment using patient or animal serum [provisional filing April 2001]; and holds equity in Reevax, BMC-JR LLC, and CeNeRx.
Dr Kalali<\/font><\/strong><\/u> is on the advisory board or speakers bureau of AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, GlaxoSmithKline, Janssen Pharmaceutica, Pfizer Inc, and Shire.
Dr Keller<\/font><\/strong><\/u> has been a consultant to or has received honoraria from Collegium, Cypress Bioscience, Cyberonics, Eli Lilly and Co, Forest Laboratories, Inc, Janssen Pharmaceutica, Organon, Otsuka America Pharmaceutical, Inc, Pfizer Inc, Pharmastar, Sepracor, Vela Pharmaceuticals Inc, and Wyeth Pharmaceuticals; has received grants from or performed research for Eli Lilly and Co, Forest Laboratories, Inc, Pfizer Inc, and Wyeth Pharmaceuticals; and has been on the advisory board of Abbott Laboratories, Bristol-Myers Squibb, Cyberonics, Cypress Bioscience, Eli Lilly and Co, Forest Laboratories, Inc, GlaxoSmithKline, Janssen Pharmaceutica, Novartis, Organon, Pfizer Inc, Sepracor, and Wyeth Pharmaceuticals.
Dr Charney<\/font><\/strong><\/u> has consulting agreements with Abbott Laboratories, AstraZeneca, Bristol-Myers Squibb, Cyberonics, Gene Logic Inc, the Institute of Medicine, Neurogen Corp, the Neuroscience Education Institute, Novartis Pharmaceuticals Corp, OREXIGEN Therapeutics, Inc, Organon International, Otsuka America Pharmaceutical, Inc, Quintiles Transnational<\/font><\/strong>, and Sepracore Inc; and has a confidentiality agreement with Forest Laboratories, Inc, and Novartis Pharmaceuticals Corp.
Dr Schatzberg<\/font><\/strong><\/u> is a consultant to Eli Lilly and Co, Wyeth Pharmaceuticals, Corcept Therapeutics, Bristol-Myers Squibb, Novartis, Abbott Laboratories, Forest Laboratories Inc, Quintiles Transnational<\/font><\/strong>, and Lundbeck; is a cofounder of Corcept Therapeutics and has equity in Forest Laboratories, Pfizer Inc, and Merck and Co; and has received research funding from GlaxoSmithKline and Wyeth Pharmaceuticals.<\/sup><\/div>\n<\/blockquote>\n<\/td>\n<\/tr>\n<\/table>\n

At the time, I was focused on the fact that this article was accepted in May 2006, just a few months before Drs. Carrol and Rubin challenged<\/font><\/strong><\/u><\/a> Dr. Nemeroff’s article in the journal he edited [Neuropsychopharmacology] and Dr. Nemeroff ended up stepping down as editor because of undeclared conflicts of interest. Last month, I was thinking about Nemeroff’s hubris in publishing such a PHARMA-friendly article and the irony that all<\/u> the authors in bold were later shown to have used ghost-writer Sally Laden and STI to write articles [paid by GSK][roaches…<\/font><\/strong><\/u><\/a>]. Yesterday [a walk on the wrong side side of the street?…<\/font><\/a><\/strong><\/u>], I was looking at the same article focusing on Martin Keller continuing to be a PHARMA sign-on lackey even after his poor show with Study 329. Now, I’m looking at the same article from yet another angle.<\/p>\n

This article iteslf is actually a complaint against the FDA and the media. After years of haggling, the FDA finally had a hearing about the complaint that Paxil and the other SSRI’s could cause suicidality in some adolescents, and subsequently required warnings to be appended to these drugs for children and adolescents. Nemeroff et al are implying that the suicidality thing might have been overdone, and as a result, prescription rates had fallen dramatically in the younger age group. Here’s the kicker – their argument was that kids are being deprived of effective treatment because of the FDA and media. Unbelievable! But you already knew that. <\/p>\n

So why are Dr. Nemeroff, Dr. Charney, Dr. Keller, and Dr. Schatzberg – all Department Chairmen of prestigious Departments of Psychiatry – writing this article?<\/font><\/strong> None of them are even Child and Adolescent Psychiatrists! I expect we would all suspect that they were PHARMA prostitutes, and that was why they were writing [or signing on to] this article. But who was getting<\/strike> paying them to do it? That lead me to get curious about those people in the author list I’d never heard of a month ago, but I was still too naive to look them up [so I put them in a background color] – Amir Kalali MD<\/font>, … Susan E. Lenderts, Elisa F. Cascade, Hugo Stephenson MD<\/font>.<\/p>\n

Who are Amir Kalali MD, Susan E. Lenderts, Elisa F. Cascade, and Hugo Stephenson MD?<\/font><\/strong>  They all work for Quintiles Transnational<\/font><\/strong><\/u><\/a>, the largest Clinical Research Organization<\/font><\/strong> in the world. That’s who:<\/div>\n